US FDA Approves AstraZeneca New Tablet Formulation of Calquence
The US FDA approved the new tablet formulation of Calquence by AstraZeneca in the United States for all current indications, including patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and patients with relapsed mantle cell lymphoma. The approval by the US FDA was based on results from the ELEVATE-PLUS trials presented at the […]
Continue Reading